Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 1997

View Archived Issues

Pharmacyclics grants Alcon rights to Lu-Tex

Novopharm Biotech's hMAb enters phase I in Canada

SciClone acquires rights to Zadaxin

Medarex's secondary cataract product enters phase III

HHS announces intention to out-license vaccine technology

Bladder efficacy demonstrated for KATP channel opener

Bayer develops compounds for neurodegenerative disorders

Protein MOT12 for diagnosis of IDDM

Farnesyltransferase inhibitors lacking a thiol moiety from Merck & Co.

Synthelabo to market milnacipran in Europe and certain other markets

Antiacne activity of oral contraceptives

Antizol cleared by FDA as first antidote for ethylene glycol poisoning

LeukoSite, Genentech collaborate on IBD therapeutic

Leukine boosts immune system in HIV-positive patients

Patient accrual in Cerestat trials will not resume

European approvals for Edronax

RSD-992: a novel 5-HT antagonist with erectogenic activity

Naramig available in Germany

New warnings added to Posicor labeling

MAb for non-Hodgkin's lymphoma now available in U.S.

CholestaGel enters phase III testing

Oral neuraminidase inhibitor advances to phase II/III

Positive phase IIa results reported for Cortecs' oral insulin

S-5920 effective in rat model of acute pancreatitis

Mechanism of exocrine pancreas secretion assessed for herbal medicine

Nutropin AQ also wins FDA approval

VIMRx and Baxter form new company focused on cell therapy

FDA Advisory Committee does not recommend approval for DepoCyt

Hemolink enters phase II trials for second indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...